Teva Pharmaceutical Industries Ltd. has entered into an agreement with Samsung Bioepis to commercialize two FDA-approved immunology biosimilars in the U.S. This deal expands Teva's biosimilar portfolio and provides Samsung Bioepis with a U.S. commercialization partner, potentially increasing market penetration for these products.
Teva Pharmaceutical Industries has secured U.S. commercialization rights for two significant immunology biosimilars from Samsung Bioepis: infliximab-abda (biosimilar to Remicade) and etanercept-ykro (biosimilar to Enbrel). This is a strategic move for Teva, bolstering its biosimilar pipeline and market share in a high-value therapeutic area. For Samsung Bioepis, it ensures a strong commercial partner for its products in the crucial U.S. market. The deal's staggered transfer of rights (etanercept-ykro immediately, infliximab-abda in Q3 2027) suggests a phased market entry strategy. This development poses a long-term competitive threat to the original drug manufacturers, Johnson & Johnson (Remicade) and Amgen (Enbrel), as biosimilars typically offer cost-effective alternatives, potentially eroding their market dominance and revenue streams. Traders should monitor the market reception of these biosimilars and their impact on the sales of the reference products.